David Lazar left the role of Director at Bryn Inc. As of November 6, 2026, Bryn Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 11, 2026, naming 2 appointments and 1 departure (Form 8-K, May 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Bryn Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: David Lazar · Role: Director · 8-K, 2026-05-11
- · In / out: In · Person: John Leo · Role: Director · 8-K, 2026-05-11
- · In / out: In · Person: Arthur Magee · 8-K, 2026-05-11
Bryn Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-11. It names 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Bryn Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-11 | Out | Director | 8-K, 2026-05-11 | ||
| 2026-05-11 | In | Director | 8-K, 2026-05-11 | ||
| 2026-05-11 | In | 8-K, 2026-05-11 |
Selling to them or working with them? See who runs Bryn Inc. now and the warning signs.
Free to see. No signup.
Watch Bryn Inc.
Get an email when Bryn Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bryn Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bryn Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bryn Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Bryn Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David Lazar, departure reported (filed 2026-05-11). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Bryn Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Bryn Inc., with the record behind each one.
Find candidates like Director at Bryn Inc.Every change, in the filing's words
Departing: David Lazar, Director
Management Pursuant to agreement between David Lazar and MEDO Healthcare, Mr. Lazar resigned on April 24, 2026 from his positions as sole officer and director of the Registrant.
Appointed: John Leo, Director
Prior to resigning, Mr. Lazar appointed John Leo to serve upon Mr. Lazar's resignation as sole director and CEO of the Registrant.
Appointed: Arthur Magee
Mr. Lazar also appointed Arthur Magee, an affiliate of John Leo, to serve upon Mr. Lazar's resignation as CFO and Secretary of the Registrant.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers On April 24, 2026 MEDO Healthcare LLC, an Iowa limited liability company, purchased 10 million shares of the Registrant's Series A-1 Preferred Stock from Custodian Ventures LLC, the personal holding company of David Lazar, who was sole director and officer of the Registrant on and prior to April 24, 2026.
- MEDO Healthcare paid to Custodian Ventures for the shares $175,000 in cash.
- The funds used to purchase the shares were contributed to MEDO Healthcare by members of that company from their personal assets.
- Security Ownership Each share of Series A-1 Preferred Stock has the voting power of 250 common shares.
- Therefore, the 10 million shares of Series A-1 Preferred Stock have the voting power of 2.5 billion common shares.
- As there are 450 million shares of common stock outstanding, the Series A-1 Preferred Stock purchased by MEDO Healthcare LLC have 84.7% of the voting power in the Registrant.
- The following table sets forth information known to us with respect to the beneficial ownership of each class of our voting stock as of the date of this Report by the following: each shareholder known by us to own beneficially more than 5% of either class of our voting stock, John Leo, our Chief Executive Officer and sole director, and all directors and executive officers as a group.
Tools for this story
Each opens in a new tab, filled in for Bryn Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.